Innovative Drug Platform Ambagon Therapeutics specializes in developing small molecules that target difficult-to-drug proteins by stabilizing critical protein interactions, opening opportunities for partnerships in drug discovery and development across oncology and neurodegenerative diseases.

Recent Funding & Growth With a recent Series A financing of $85 million and a revenue range of $1M to $10M, Ambagon is experiencing significant financial backing and growth potential, making it an attractive partner for co-development and investment collaborations.

Expanding Therapeutic Focus Beyond cancer, Ambagon is actively working on therapies for Parkinson's disease and other conditions by targeting protein interactions, providing potential avenues for joint research or licensing opportunities in neurology and complex disease areas.

Technological Expertise Utilizing a diverse tech stack including molecular platforms and data analysis tools, Ambagon offers potential service collaborations or technology licensing opportunities to enhance drug discovery efficiency.

Strategic Collaborations The company's engagement with academic institutions like Eindhoven University of Technology and advisory boards signifies openness to strategic partnerships for innovative research and early-stage co-investment in cutting-edge therapeutic candidates.